Evaluation of Continuous Symptom Treatment of ADHD
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that atomoxetine administered orally,
once a day, at doses up to 1.4 mg/kg/day for approximately 6 weeks given in the morning is
superior to placebo in children with ADHD.